AVI Biopharma, the Portland, OR-based developer of RNA-based therapies, said today it has been awarded part of a $2.5 million contract from the U.S. Department of Defense to develop a drug for Duchenne Muscular Dystrophy. The contract, awarded to researchers at the Children’s National Medical Center in Washington D.C., will support animal studies to develop AVI-4658. AVI (NASDAQ: [[ticker:AVII]]) will serve as a subcontractor, the company said.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
